Abstract:Every common psychiatric syndrome is genetically, neurobiologically and clinically heterogeneous. This heterogeneity may reflect the dimensional variability of a single illness with common etiology, varying in severity. Alternatively, as in many areas of medicine, it may reflect different discrete types of illness leading to similar alterations of mood or behavior. Resolving uncertainty as to the nature of heterogeneity in psychiatric illness is crucial for advancing the development of novel therapeutics and improving the precision with which pharmacological interventions are chosen for specific patients. Recent work resolving illness heterogeneity has shown promise in identifying biologically distinct patient subgroups within common psychiatric syndromes. This progress offers hope for the longer-term aim of enhancing our understanding of biological alterations associated with psychiatric syndromes, so that drug development and pharmacological interventions can shift towards altering specific targeted biological processes, instead of working to change complex behavioral features that may represent the final common pathway of different biological illness mechanisms. Using approaches such as neuroimaging and peripheral immune markers, studies have identified subgroups with different patterns of biological features that provide translational targets for novel drug development programmes, and may, in the longer term, together with psychological and social perspectives, more closely link diagnostics and therapeutics in psychiatry. So far, multiple discrete subgroups have been identified, and these have been associated with clinical features. Work is now needed to improve the validity and reliability of biologically derived subtypes, and better characterize their clinical, developmental and psychosocial features. This is required to establish their clinical utility for predicting illness course and response to different therapies, and to determine how biologically distinct features of patient subgroups can guide the development of novel therapies targeting those alterations.

Subtypes of substance dependence and abuse: implications for diagnostic classification and empirical research

Subtypes for classifying adolescents with marijuana use disorders: construct validity and clinical implications

Nosological considerations in the diagnosis of substance use disorders.

Substance, not semantics, is the issue: comments on the proposed addiction criteria for DSM-V.

Subtypes of alcoholism and their role in therapy

Types of alcoholics: concurrent and predictive validity of some common classification schemes

The type A/type B distinction. Subtyping alcoholics according to indicators of vulnerability and severity.

The classification of alcoholics: Typology theories from the 19th century to the present

Substance-use disorders in DSM-III-R: evidence for the dependence syndrome across different psychoactive substances

Subtypes of cocaine abusers: Support for a Type A–Type B distinction.

Introduction: Method and Theory in the Classification of Alcoholicsa

Insights from genetically stratified analyses comparing subtypes of alcohol misuse

Typologies in alcoholism: An overview

Alcoholic typologies: Historical evolution and empirical evaluation of some common classification schemes

Classification and forms of inebriety: Historical antecedents of alcoholic typologies

Searching for diagnoses and subgroups: a suggestion for criteria

Co-occurrence of substance use disorders with other psychiatric disorders: Implications for treatment services

Substance abuse: alcohol use disorders

Types of alcoholics, I: Evidence for an empirically derived typology based on indicators of vulnerability and severity

Biological Subtyping of Psychiatric Syndromes As a Pathway for Advances in Drug Discovery and Personalized Medicine

Alcohol and drug use history, patterns and problems